Age-related Macular Degeneration (AMD) Market Share, Size, Trends, Industry Analysis Report
By Drugs (Lucentis, Eylea, Avastin, Others); By Product; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2026 - 2034
- Published Date: Sep-2025
- Pages: 114
- Format: PDF
- Report ID: PM1128
- Base Year: 2025
- Historical Data: 2021 - 2024
The global Age-related Macular Degeneration (AMD) Market was valued at USD 12.64 billion in 2025 and is expected to grow at a CAGR of 8.0% during the forecast period. Rising Research and Development (R&D) investments, as well as increased approvals for new medications, are important drivers of Age-related Macular Degeneration (AMD) market expansion.
Key Insights
- North America held the largest share of 52.65% in 2025. This dominance is due to a high prevalence of AMD in the aging population and growing patient awareness.
- Asia Pacific is projected to witness the fastest growth at a 90% CAGR. The high prevalence of AMD contributes to the region’s rapid growth.
- The wet AMD segment held the largest share of 85.6% in 2025. This is primarily due to the availability of approved and highly effective anti-vascular endothelial growth factor (Anti-VEGF) drug treatments.
- The Eylea segment held the largest share of 43.2% in 2025. This is owing to its established efficacy in treating major retinal diseases.
- The intravenous segment held revenue share of 9.9% in 2025. Intravenous will be most effective delivery method for anti-VEGF agents treating wet age-related macular degeneration.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Market Statistics
- 2025 Market Size: USD 12.64 billion
- 2034 Projected Market Size: USD 25.18 billion
- CAGR (2026-2034): 8.0%
- North America: Largest market in 2025
Industry Dynamics
- The rapidly expanding global geriatric population is a primary growth factor, significantly increasing the patient pool susceptible to vision loss.
- Technological advancements, especially in anti-VEGF therapies, are major drivers, offering more durable treatment options and easing the patient burden.
- A growing focus on research and development (R&D) for dry-form treatments is also shaping the industry outlook.
-market-size-by-region-2020-2034.png)
To Understand More About this Research: Request a Free Sample Report
AI Impact on the Market
- AI algorithms, particularly those using deep learning, can analyze retinal images from fundus photography or optical coherence tomography (OCT) scans with high speed and precision.
- AI models can analyze complex imaging data to predict how a patient's AMD will progress and how they might respond to treatments, such as anti-vascular endothelial growth factor (anti-VEGF) injections.
- By automating the analysis of retinal images, AI quickly flag images that show signs of AMD.
For instance, in October 2021, Roche has announced the approval of Susvimo (ranibizumab injection) 100 mg/mL by the US Food and Drug Administration (FDA) of intravenous injection use through an ocular augmentation in people with age-related macular degeneration (AMD) who have earlier received two of the anti-vascular endothelial growth factor (VEGF) infusions.
Also, the United States Food and Drug Administration (FDA) granted GT005; an experimental, one-time AAV gene therapy received fast-track designation in September 2020. Gyroscope Therapeutics Limited has developed GT005, which is a one-time experimental gene treatment for GA owing to AMD that is given under the retina and is based on AAV2.
What is Age-related Macular Degeneration (AMD) Market?
The AMD market involves the research and development, manufacturing, and supply of diagnostics, pharmaceuticals, and therapeutics for the treatment of AMD. AMD is a progressive eye disease that affects the macula, causing loss of central vision over time. It is most common in individuals aged 50 years and older and is categorized into dry and wet forms
Industry Dynamics
Growth Drivers
The global burden of AMD continues to rise at an unprecedented speed as the global population grows and the demographics reflect a majority of older people. AMD is a primary cause of visual loss in the elderly, according to the National Eye Institute. Furthermore, those over the age of 60 are at a higher risk of having the condition.
AMD is predicted to become more common as the world's population ages, with a higher frequency in Western countries. According to the Globe Health Organization, there are currently around 1.1 billion tobacco users in the world, with that figure likely to double by 2050 if current trends continue. As a result, cigarette use is thought to be a major contributor to the global increase in AMD prevalence.
Furthermore, as the global population of people aged 60 and up grows, so does the prevalence of AMD. According to the United Nations' Globe Population Prospects report, there were around 962 million individuals aged 60 and more in the world in 2017, with the number predicted to more than double by 2050.
According to WHO, myopia and high myopia were expected to affect around 52.0% and 10.0% of the global population, respectively, by 2050. The prevalence of myopia is high in East Asia, where China, Japan, the Republic of Korea, and Singapore.
Which Innovations are Transforming the Age-Related Macular Degeneration (AMD) Market?
Advances in biotechnology, gene therapy, and digital health are a few key innovations in the AMD market. Many emerging treatments, including gene and stem cell therapies, aim to preserve or restore retinal function. They offer long-term solutions beyond conventional anti-VEGF injections. Development of new long-acting drug delivery systems and complement pathway inhibitors enhances treatment adherence. It also addresses unmet needs in dry AMD. Further, the integration of AI-based diagnostics and teleophthalmology platforms enables personalized monitoring, early detection, and remote patient management. These innovations transform AMD management through less-invasive and patient-centric treatment models.
- Gene Therapy: Targets defective genes to slow down degeneration or restore retinal function. It provides potential long-term treatment for wet AMD.
- Stem Cell Therapy: Use of human embryonic or induced pluripotent stem cells. It helps regenerate RPE (retinal pigment epithelium) cells damaged by AMD.
- Long-Acting Anti-VEGF Agents: Rising emphasis on reducing injection frequency through port delivery systems and sustained-release drug formulations.
- Complement Pathway Inhibitors: Complement system proteins are targeted to slow the progression of geographic atrophy in dry AMD patients.
- AI and Digital Diagnostics: AI use for early AMD detection, disease progression monitoring, and image analysis using retinal imaging.
-market-size-worth-$25.40-billion-by-2034.png)
Wet AMD vs Dry AMD / Anti-VEGF Drugs vs Emerging Therapies
|
Segment |
Definition |
Treatment Strategy |
Commercial Significance |
|
Wet AMD |
Rapid vision deterioration caused by blood vessels developing abnormally |
Anti-VEGF injection |
High clinical need |
|
Dry AMD |
Slow vision deterioration from degeneration of retinal tissue |
Vitamin supplements, new medicines |
Most prevalent type |
|
Anti-VEGF Medicines |
Inhibit abnormal growth of blood vessels |
Eye injections at regular intervals |
Common therapy for wet AMD |
|
New Therapies |
Gene and cell-based approaches |
Potential for long-term treatment or cure |
Future growth driver |
Report Segmentation
The market is primarily segmented based on product, drugs, route of administration, distribution channel, and region.
|
By Product |
By Drugs |
By Route of Administration |
By Distribution Channel |
By Region |
|
|
|
|
|
-market-by-product-analysis-2020-2034.png)
Insight by Product
Based on the product segment, the wet AMD segment is expected to be the most significant revenue contributor in the global Age-related Macular Degeneration (AMD4) market. Wet age-related macular degeneration is the start of normal blood vessel growth beneath the retina. The expanding geriatric population around the world is producing a high-level demand in the wet age-related macular degeneration market since AMD is the most prevalent cause of significant loss of vision in those over 50 years of age.
The growth is further driven by the higher prevalence of wet AMD in aging populations, the rapid progression of the disease requiring immediate treatment, and increasing awareness about early diagnosis. Additionally, advancements in biologics and anti-VEGF therapies, rising healthcare expenditure, and ongoing clinical trials for novel treatments are further propelling demand in this segment, solidifying its dominant market position.
Geographic Overview
North America had the largest revenue share in the global market in 2025. The rising incidence of the geriatric population and age-related macular degeneration, the participation of important market players, and increased research and development activities are some of the forces influencing Age-related Macular Degeneration (AMD) market expansion in the North American area. Furthermore, the American Macular Degeneration Foundation (AMDF) in the United States disseminated this information to warn AMD patients and eye care professionals about the potential danger.
Around the world, advanced AMD is a primary cause of permanent blindness and visual impairment. As a result, the market is growing as AMD's load grows. Further, Wet age-related macular degeneration is one of the leading causes of visual loss in adults over 65, according to the Canadian Ophthalmological Society.
One of its studies, released in 2019, predicted that by 2032, at least one out of every four Canadians would have age-related macular degeneration. As a result of the aforementioned factors, the market in the region is predicted to develop significantly over the forecast period.
Moreover, Asia Pacific is expected to witness a high CAGR in the global Age-related Macular Degeneration (AMD) market. The sale of medications for exudative AMD in APAC is currently insignificant due to a lack of accessibility and expensive drug costs. The region, however, has a high prevalence of AMD, making it a potentially growing market.
Furthermore, in APAC, the presence of companies involved in the marketing and research of exudative AMD medicines is fairly low. In addition, the region accounts for more than a third of all age-related macular degeneration cases recorded globally therefore demand for wet age-related macular degeneration medications is projected to increase dramatically in the future years.
-market-trends-by-region-2020-2034.png)
Competitive Insight
There is moderate consolidation in the AMD market with a few leading pharmaceutical and biotech companies occupying the majority share, particularly with regard to anti-VEGF treatments. The competition is largely based on innovation in treatments for retinal diseases. The current competition is driven towards improving efficacy, reducing injection intervals, and developing additional uses for drugs.
An influx of biosimilars and advanced biologics is intensifying competition in the industry as patents on critical drugs are expiring. Meanwhile, companies are eyeing dry AMD, an underserved indication at present, opening the door to innovation. Increasing investments in gene therapy, extended-release formulations, and combination therapies will continue to drive market competition.
Regeneron is a key player in the AMD market. It is known for its anti-VEGF drug used to treat wet AMD. The company has an established presence in the management of retinal diseases. It focuses on developing long-acting ophthalmic drugs.
Alimera Sciences is a specialized ophthalmic business that deals with products intended for the treatment of retinal diseases. It offers long-acting drug delivery technologies so that patients require fewer treatments. The company differentiates itself through specialized, sustained-release ophthalmic therapies
Some of the major players operating in the global market include:
- Acucela Inc.
- Alimera Sciences Inc.
- ALLERGAN
- Bausch & Lomb Incorporated
- Bayer AG
- F. Hoffmann La Roche
- GlaxoSmithKline PLC
- Novartis AG
- Ophthotech Corporation
- Pfizer Inc
- Regeneron Pharmaceuticals
- Rxi Pharmaceuticals Inc.
- Santen Pharmaceuticals Co.
- Valeant Pharmaceuticals International
Industry Developments
- April 2026: Regeneron Pharmaceuticals, Inc. announced that the U.S. FDA approved EYLEA HD (aflibercept) with extended dosing intervals up to 20 weeks for wet AMD and diabetic macular edema. According to Regeneron, the approval will enhance patient compliance. (source: regeneron.com)
- April 2026: Merck announced the initiation of Phase 2b/3 MALBEC trial of MK-8748, a bispecific molecule targeting VEGF and activating the Tie2 pathway. According to Merck, the trial will evaluate the biomolecule for the treatment of neovascular age-related macular degeneration. (source: merck.com)
- July 2024: Genentech (Roche) reintroduced Susvimo (100 mg/mL ranibizumab injection) in the U.S. for intravitreal use via ocular implant, indicated for the treatment of neovascular or “wet” age-related macular degeneration (nAMD). (Source: gene.com)
Age-related Macular Degeneration (AMD) Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2025 |
USD 12.64 billion |
| Market size value in 2026 | USD 13.58 billion |
|
Revenue forecast in 2034 |
USD 25.18 billion |
|
CAGR |
8.0% from 2026 - 2034 |
|
Base year |
2025 |
|
Historical data |
2021 - 2024 |
|
Forecast period |
2025 - 2034 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2026 to 2034 |
|
Segments covered |
By Product, By Drugs, By Route Of Administration, By Distribution Channel, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key companies |
Acucela Inc., Alimera Sciences Inc., ALLERGAN, Bausch & Lomb Incorporated, Bayer AG, F. Hoffmann La Roche, GlaxoSmithKline PLC, Novartis AG, Ophthotech Corporation, Pfizer Inc, Regeneron Pharmaceuticals, Rxi Pharmaceuticals Inc., Santen Pharmaceuticals Co., and Valeant Pharmaceuticals International, Inc. |
FAQ's
? The global market size was valued at USD 12.64 billion in 2025 and is projected to grow to USD 25.30 billion by 2034.
? The global market is projected to register a CAGR of 8.0% during the forecast period.
? North America dominated the market share in 2025.
? The Wet AMD segment accounted for the largest share of the market in 2025.
© 2026 Polaris Market Research and Consulting. All rights reserved
